ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,185Medicare Part D Prescriptions Filled, Including Refills

Rank: 11 out of 617

$389K Total Retail Price of All Prescriptions

Rank: 43 out of 617

361 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
66% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Illinois
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

11% of this provider’s 361 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

0% of this provider’s 7,321 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$42 was the average price of a prescription from this provider, compared to $65 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 12.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Illinois
FUROSEMIDE 567 471 1 7
SIMVASTATIN 413 365 2 3
METOPROLOL SUCCINATE 408 332 3 1
WARFARIN SODIUM 386 268 4 9
LOSARTAN POTASSIUM 360 299 5 16
LISINOPRIL 329 251 6 2
AMLODIPINE BESYLATE 317 267 7 6
POTASSIUM CHLORIDE 259 204 8 19
METOLAZONE 226 198 9 79
ATORVASTATIN CALCIUM 225 196 10 8
METOPROLOL TARTRATE 197 175 11 5
METFORMIN HCL 195 138 12 25
PANTOPRAZOLE SODIUM 191 174 13 38
LEVOTHYROXINE SODIUM 169 160 14 23
DIOVAN 162 146 15 21
CRESTOR 159 147 16 11
HYDROCHLOROTHIAZIDE 147 129 17 18
AMIODARONE HCL 135 117 18 27
LOSARTAN-HYDROCHLOROTHIAZIDE 111 100 19 47
OMEPRAZOLE 111 91 19 31
DIGOXIN 110 98 21 12
PROAIR HFA 102 84 22 97
CLOPIDOGREL 101 84 23 10
ZOLPIDEM TARTRATE 93 60 24 56
ALLOPURINOL 92 80 25 50
KLOR-CON M20 91 77 26 39
ATENOLOL 90 76 27 17
CLONIDINE HCL 89 72 28 45
HYDRALAZINE HCL 85 68 29 28
HYDROCODONE-ACETAMINOPHEN 85 48 S3 29 32
GLIPIZIDE 83 70 31 64
NIFEDIPINE ER 82 77 32 49
GLIPIZIDE ER 78 78 33 104
CARVEDILOL 71 53 34 4
ISOSORBIDE DINITRATE 70 47 35 122
ENALAPRIL MALEATE 69 57 36 22
PREDNISONE 69 56 36 93
ISOSORBIDE MONONITRATE ER 67 66 38 14
TAMSULOSIN HCL 63 57 39 59
PRAVASTATIN SODIUM 63 47 39 15
PLAVIX 63 56 39 13
TRAMADOL HCL 60 52 42 54
LEVETIRACETAM 59 16 43 212
KLOR-CON 10 55 37 44 58
NAPROXEN 52 49 45 98
VENTOLIN HFA 52 32 45 148
KLOR-CON M10 51 47 47 151
INSULIN SYRINGE 50 34 48 115
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.